Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 25G-NBOMe
Research chemicalResearch chemicalPhenethylaminePsychedelicN-benzyl (NBOMe)5-HT2A agonist

25G-NBOMe

Also known as 2C-G-NBOMe · 25G

25G-NBOMe is the N-(2-methoxybenzyl) derivative of 2C-G (a dimethyl-substituted phenethylamine). It is a potent NBOMe-class 5-HT2A agonist psychedelic, orally inactive and sub-milligram active, with the family's narrow safety margin, vasoconstriction and seizure hazards.

01 Overview

25G-NBOMe is a rare 25x-NBOMe compound derived from the 2C-G family of ring-methylated phenethylamines. It has minimal market presence and no controlled human data.

Available information is anecdotal and analytical. As with all NBOMes, the sub-milligram active range and steep dose-response mean small dosing errors can produce severe cardiovascular and neurological toxicity.

02 Mechanism

Potent agonist at 5-HT2A receptors; N-2-methoxybenzyl substitution increases 5-HT2A affinity of the 2C-G scaffold by orders of magnitude.

03 Dosing

TierDoseRouteNotes
Threshold200–500 µgSublingualEstimated; sparse data.
Common500–1500 µgSublingualAnecdotal only.

04 Effects

EffectMagnitudeEvidence
Psychedelic effectsVisuals and altered cognition; 2C-G parent is associated with long duration.6-12 hAnecdotal
StimulationBody load and tension typical of the NBOMe series.moderateAnecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
VasoconstrictionCold extremities, hypertension and tachycardia.SevereCommonAnecdotal
Seizures and hyperthermiaOverdose can cause agitation, seizures and hyperthermia as in the class.Life-threateningUncommonAnecdotal

07 References

N-benzyl phenethylamines: a growing family of designer hallucinogensDrug Testing and Analysis, 2014
EMCDDA NBOMe overviewEMCDDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.